Anti-CD20 monoclonal antibody for post-transplant lymphoproliferative disorders.

Suppr

超能文献

作者信息

Faye A, Van Den Abeele T, Peuchmaur M, Mathieu-Boue A, Vilmer E

出版信息

Lancet. 1998 Oct 17;352(9136):1285. doi: 10.1016/S0140-6736(05)70493-1.

DOI:10.1016/S0140-6736(05)70493-1

PMID:9788467

Abstract

摘要

相似文献

Anti-CD20 monoclonal antibody for post-transplant lymphoproliferative disorders.

Lancet. 1998 Oct 17;352(9136):1285. doi: 10.1016/S0140-6736(05)70493-1.

Long-term remission of an EBV-positive B cell lymphoproliferative disorder associated with rheumatoid arthritis under methotrexate with anti-CD20 monoclonal antibody (Rituximab) monotherapy.

Leukemia. 2002 Oct;16(10):2173-4. doi: 10.1038/sj.leu.2402588.

Successful treatment of a patient with Epstein-Barr virus-positive B-cell lymphoproliferative disorder resembling post-transplant lymphoproliferative disorder using single-agent rituximab.使用利妥昔单抗单药成功治疗一名患有类似于移植后淋巴细胞增生性疾病的爱泼斯坦-巴尔病毒阳性B细胞淋巴增生性疾病的患者。

J Clin Oncol. 2011 Aug 1;29(22):e658-60. doi: 10.1200/JCO.2011.34.8656. Epub 2011 Jun 6.

Epstein-Barr virus polymerase chain reaction-negative stage IV post-transplant lymphoproliferative disorder in a heart transplant patient treated with rituximab.接受利妥昔单抗治疗的心脏移植患者中，爱泼斯坦-巴尔病毒聚合酶链反应阴性的IV期移植后淋巴增殖性疾病

J Heart Lung Transplant. 2008 Aug;27(8):928-31. doi: 10.1016/j.healun.2008.05.020. Epub 2008 Jul 3.

Long-lasting hypogammaglobulinemia following rituximab administration for Epstein-Barr virus-related post-transplant lymphoproliferative disease preemptive therapy.利妥昔单抗用于预防爱泼斯坦-巴尔病毒相关的移植后淋巴细胞增生性疾病治疗后出现的持久性低丙种球蛋白血症。

J Hematother Stem Cell Res. 2003 Feb;12(1):9-10. doi: 10.1089/152581603321210082.

CD-20 expression in post-transplant lymphoproliferative disorders: treatment with rituximab.

Am J Hematol. 2000 Oct;65(2):171-3. doi: 10.1002/1096-8652(200010)65:2<171::aid-ajh14>3.0.co;2-z.

Epstein-Barr virus-driven lymphoproliferative disorder post-CAMPATH-1H (alemtuzumab) in refractory polymyositis.

Rheumatology (Oxford). 2011 Apr;50(4):810-2. doi: 10.1093/rheumatology/keq429. Epub 2011 Jan 5.

Post-transplantation lymphoproliferative disorder of recipient origin in a boy with acute T-cell leukemia with detection of B-cell clonality 3 months before stem cell transplantation.

Haematologica. 2005 Nov;90 Suppl:ECR27.

Multifocal polyclonal Epstein-Barr virus-associated B-cell lymphoproliferative disorder secondary to azathioprine therapy successfully treated with rituximab.硫唑嘌呤治疗继发的多灶性多克隆性爱泼斯坦-巴尔病毒相关B细胞淋巴增殖性疾病，用利妥昔单抗成功治疗。

Leuk Lymphoma. 2010 Jan;51(1):174-7. doi: 10.3109/10428190903402029.

Epstein-Barr viral infection and posttransplantation lymphoproliferative disorders.

Liver Transpl Surg. 1995 Sep;1(5 Suppl 1):100-8.

引用本文的文献

Rituximab is Indispensable for Pediatric Heart Transplant Recipients Developing Post Transplant Lymphoproliferative Disorders.利妥昔单抗对于发生移植后淋巴细胞增生性疾病的小儿心脏移植受者不可或缺。

Iran J Ped Hematol Oncol. 2013;3(3):125-34. Epub 2013 Jul 22.

Biologic agents in islet transplantation.胰岛移植中的生物制剂。

Curr Diab Rep. 2013 Oct;13(5):713-22. doi: 10.1007/s11892-013-0414-8.

Reduction of immunosuppression as initial therapy for posttransplantation lymphoproliferative disorder(★).作为移植后淋巴组织增生性疾病（★）初始治疗的免疫抑制药物减量。

Am J Transplant. 2011 Feb;11(2):336-47. doi: 10.1111/j.1600-6143.2010.03387.x. Epub 2011 Jan 10.

Treatment with rituximab in benign and malignant hematologic disorders in children.利妥昔单抗在儿童良性和恶性血液系统疾病中的治疗应用。

J Pediatr. 2007 Apr;150(4):338-44, 344.e1. doi: 10.1016/j.jpeds.2006.12.038.

Post-transplant lymphoproliferative disorder in children: incidence, prognosis, and treatment options.儿童移植后淋巴细胞增生性疾病：发病率、预后及治疗选择

Paediatr Drugs. 2005;7(1):55-65. doi: 10.2165/00148581-200507010-00005.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验